Georgios Sflomos
EPFL SV ISREC UPBRI
SV 2830 (Bâtiment SV)
Station 19
1015 Lausanne
+41 21 693 59 18
Office:
SV 2830
EPFL › SV › ISREC › UPBRI
Website: https://brisken-lab.epfl.ch
Expertise
Pre-clinical Models, Invasive Lobular Carcinoma, Extracellular Matrix, Metastasis
Current work
I currently lead Working Group 4 for ILC Model Systems. This initiative is a crucial part of the EU-funded COST Action LOBSTERPOT (CA19138), orchestrated by the European Lobular Breast Cancer Consortium (ELBCC). Our goal is to enhance the understanding, diagnosis, and treatment of ILC, thereby making significant strides in the fight against this disease. As a member of the scientific advisory board subcommittee of the Lobular Breast Cancer Alliance (LBCA), I am actively involved in promoting the development of innovative research models for ILC.
I possess extensive expertise in molecular oncology and translational research. Over the past 8 years, my focus has been on the most common special histological breast cancer subtype, a highly hormone-sensitive malignacy known as invasive Lobular Breast Carcinoma (ILC).
My drive stems from a deep passion for uncovering hidden biological phenomena in translational oncology research. My expertise lies in pioneering preclinical cancer models, particularly ER-positive breast cancers, addressing this subtype's lack of clinically relevant preclinical models. I have achieved significant breakthroughs, including developing a game-changing in vivo intraductal model that closely mimics patient responses to treatments and metastasis as well as cutting-edge experimental methods and tools that have expanded the horizons of preclinical and translational ILC research.
My drive stems from a deep passion for uncovering hidden biological phenomena in translational oncology research. My expertise lies in pioneering preclinical cancer models, particularly ER-positive breast cancers, addressing this subtype's lack of clinically relevant preclinical models. I have achieved significant breakthroughs, including developing a game-changing in vivo intraductal model that closely mimics patient responses to treatments and metastasis as well as cutting-edge experimental methods and tools that have expanded the horizons of preclinical and translational ILC research.